Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiovascular, Renal, and Bone Dysplasia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPR3 (Natriuretic Peptide Receptor C) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPR3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed with native glycosylation. Theoretical MW confirmed. |
View NPR3 Products |
| Gene Delivery | NPR3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction; ideal for internalization assays and receptor cycling studies. |
View NPR3 Products |
| Benchmark Ab | Anti-NPR3 (Research Grade Recombinant Antibody) Positive control for binding validation and assay standardization. |
View NPR3 Products |
| Validator | NPR3 siRNA Set For knockdown verification and specificity confirmation; 3'UTR-targeted to avoid off-target effects. |
View NPR3 Products |
| Related Target A | NPR1 (Natriuretic Peptide Receptor 1 / GC-A) Guanylyl cyclase active receptor; signaling receptor for ANP/BNP; critical counter-screening target. |
View NPR1 Products |
| Related Target B | NPR2 (Natriuretic Peptide Receptor 2 / GC-B) CNP signaling receptor; mandatory selectivity panel for bone and vascular development studies. |
View NPR2 Products |
| Related Ligand | NPPA (ANP) / NPPB (BNP) / NPPC (CNP) Endogenous ligands available as active recombinant proteins for competition binding assays. |
View NPPA Products / View NPPB Products / View NPPC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation for toxicology | Human/Mouse/Cyno NPR3 ortholog proteins available with >95% purity; Sequence Verified by Mass Spec. |
| Receptor internalization assays & clearance mechanism validation | HEK293-expressed ECD-Fc (native glycosylation) for robust cellular binding tracking; Lentivirus-stable cell lines preserve native conformation for flow cytometry-based uptake assays. |
| Subfamily counter-screening (NPR1 vs NPR2 vs NPR3) | Homolog panel proteins (NPR1, NPR2, NPR3) strictly verified by mass spec and sequence analysis for off-target screening. |
| Lack of specific controls | Clinical benchmark antibodies (research grade biosimilars) included for assay standardization and positive control. |
| False positives in cellular assays | Validated siRNA set for specificity checks; optional shRNA lentivirus for stable knockdown. |
Live NPR3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NPR3-targeted therapeutics is intensifying, with major players shifting focus from traditional systemic vasodilators to targeted biologics. As a primary clearance receptor for natriuretic peptides (ANP, BNP, CNP), blockade of NPR3 prevents ligand internalization and degradation, thereby prolonging the half-life of endogenous cardioprotective peptides. First-generation therapies are advancing for cardiovascular and bone growth disorders; the next wave targets highly selective NPR3 antagonists that avoid cross-reactivity with NPR1 and NPR2. Simultaneously, exploratory modalities include NPR3-targeted ADCs for cardiac-specific payload delivery and bispecific constructs that activate NPR1 while blocking NPR3 clearance. The therapeutic window hinges on precise receptor occupancy without disrupting basal hemodynamics. Clinically relevant mutations such as rs1433125500 and rs1741953064 (associated with BOMOS and loss of plasma membrane localization) highlight the need for mutant-specific assay tools to study receptor trafficking defects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Clearance Inhibition) | Novartis, Regeneron, Amgen, Academic Consortia | Heart Failure (HFrEF/HFpEF), Hypertension, Metabolic Disorders, Bone Dysplasia | High-affinity binding to ECD (SPR/BLI); receptor occupancy assay; sequence-verified >95% purity NPR3 antigen. |
| ADC (Targeted Cardiac Payload) | Emerging Biotech | Cardiac Fibrosis, Cardiomyopathy | Internalization assay using lentivirus-stable cell lines with native conformation; endotoxin-controlled reagents. |
| Peptide-Based Therapies (Antagonists & Resistant Variants) | Novo Nordisk, Sanofi, Biotech Peptide Platforms | Heart Failure, Hypertension, Acute Decompensated Heart Failure | Competition binding assay vs endogenous ANP/BNP; cross-species affinity panel; binding affinity assay (need high-purity ECD-Fc). |
| Small Molecule (Allosteric Inhibitors) | Novartis, Pfizer, Pharma Screening Programs | Cardiovascular Disease, Chronic Hypertension | Selectivity panel vs NPR1/NPR2 (homolog proteins required); dose-response validation. |
Key Genetic Variants & Functional Impact
Specific mutations in NPR3 have been documented to impair receptor function. Notable examples include rs1433125500 and rs1741953064, both reported in UniProt (P17342) as causing loss of plasma membrane localization in BOMOS. These variants underscore the importance of using mutant-specific recombinant proteins and cell-based assays to evaluate drug effects on receptor trafficking. TarMart offers custom mutagenesis services and mutant ECD-Fc proteins for such research.